Last Updated:
10 Mar 2026, 03:29:40 PM (IST)
Aarey Drugs & Pharmaceuticals Limited
NSE: AAREYDRUGS BSE: AAREYDRUGS
NSE
69.24
-0.17 (-0.24%)
Prev Close
69.41
Open Price
70.01
Volume
34,952
Today Low / High
69 / 71.4
52 WK Low / High
32.85 / 100
Range
66 - 73
BSE
69.67
0.47 (0.68%)
Prev Close
69.2
Open Price
70.82
Volume
305
Today Low / High
69.36 / 71.86
52 WK Low / High
31.3 / 100
Range
66 - 73
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 69.24 (target range: 66 - 73), reflecting a change of -0.17 (-0.24492%). On the BSE, it is listed at 69.67 (target range: 66 - 73), showing a change of 0.47 (0.67919%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
02 Mar
74.94
-7.03%
27 Feb
77.02
-0.38%
26 Feb
72.99
7.75%
25 Feb
74.00
-3.04%
24 Feb
79.64
-5.15%
23 Feb
85.99
-6.40%
20 Feb
72.48
8.33%
Aarey Drugs & Pharmaceuticals Limited Graph
Aarey Drugs & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarey Drugs & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 69.24, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 69.67 | 70.37 | 63.33 - 77.40 |
| 71.06 | 56.85 - 85.28 | ||
| 71.76 | 50.23 - 93.29 | ||
| Bearish Scenario | 69.67 | 68.97 | 62.08 - 75.87 |
| 68.28 | 54.62 - 81.93 | ||
| 67.58 | 47.31 - 87.85 |
Overview of Aarey Drugs & Pharmaceuticals Limited
ISIN
INE198H01019
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
280,240
Market Cap
1,975,444,290
Last Dividend
0
Official Website
IPO Date
2021-08-06
DCF Diff
117.99
DCF
-46
Financial Ratios Every Investor Needs
Stock Dividend of AAREYDRUGS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2018-12-13 | December 13, 18 | 0.1 | 0.1 | 2018-12-14 | 2018-12-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 473.94 Cr | 464.81 Cr | 9.13 Cr | 0.0193 | 0.00 Cr | 1.34 Cr | 0.31 Cr | 4.02 Cr | 1.43 | 12.06 Cr | 0.0085 |
| 2024-03-31 | 395.10 Cr | 381.90 Cr | 13.20 Cr | 0.0334 | 0.00 Cr | 0.42 Cr | 2.82 Cr | 4.68 Cr | 1.84 | 11.42 Cr | 0.0119 |
| 2023-03-31 | 418.96 Cr | 403.84 Cr | 11.51 Cr | 0.0275 | 0.00 Cr | 0.88 Cr | 13.53 Cr | 3.77 Cr | 1.49 | 10.45 Cr | 0.0090 |
| 2022-03-31 | 491.61 Cr | 472.06 Cr | 19.54 Cr | 0.0398 | 0.00 Cr | 0.61 Cr | 11.77 Cr | 6.55 Cr | 2.72 | 14.06 Cr | 0.0133 |
| 2021-03-31 | 347.89 Cr | 337.79 Cr | 10.10 Cr | 0.0290 | 0.00 Cr | 0.32 Cr | 3.87 Cr | 6.51 Cr | 2.79 | 11.67 Cr | 0.0187 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.47 Cr | 238.27 Cr | 99.79 Cr | 138.4805 Cr | 34.86 Cr | 33.38 Cr | 45.48 Cr | 16.22 Cr | 0.00 Cr | 0.00 Cr | 3.10 Cr | 96.8804 Cr |
| 2024-03-31 | 1.59 Cr | 303.29 Cr | 170.52 Cr | 132.7734 Cr | 31.35 Cr | 29.76 Cr | 71.99 Cr | 12.96 Cr | 0.00 Cr | 0.00 Cr | 2.09 Cr | 166.5469 Cr |
| 2023-03-31 | 0.71 Cr | 291.32 Cr | 173.91 Cr | 117.4138 Cr | 37.72 Cr | 37.01 Cr | 65.18 Cr | 13.94 Cr | 5.28 Cr | 0.00 Cr | 1.19 Cr | 168.1349 Cr |
| 2022-03-31 | 0.19 Cr | 245.17 Cr | 131.53 Cr | 113.6373 Cr | 14.16 Cr | 13.97 Cr | 56.12 Cr | 14.47 Cr | 0.89 Cr | 0.00 Cr | 2.80 Cr | 126.7362 Cr |
| 2021-03-31 | 0.64 Cr | 233.04 Cr | 134.18 Cr | 98.8605 Cr | 18.02 Cr | 17.38 Cr | 46.93 Cr | 14.26 Cr | 0.00 Cr | 0.00 Cr | 0.40 Cr | 130.8039 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.8948 Cr | -5.9394 Cr | 4.9237 Cr | -4.3096 Cr | -0.1211 Cr | 1.4733 Cr | -5.2044 Cr | 4.0239 Cr | 3.2337 Cr | 0.0000 Cr | -10.8045 Cr |
| 2024-03-31 | -2.9938 Cr | -1.7023 Cr | 5.5848 Cr | -3.7161 Cr | 0.8886 Cr | 1.5944 Cr | -0.7223 Cr | 4.6837 Cr | -1.1362 Cr | 0.0000 Cr | -5.8566 Cr |
| 2023-03-31 | -1.2811 Cr | 0.4410 Cr | 1.3540 Cr | -2.3251 Cr | 0.5139 Cr | 0.7058 Cr | -1.0440 Cr | 6.0151 Cr | 4.2211 Cr | 0.0000 Cr | -15.1352 Cr |
| 2022-03-31 | -4.4930 Cr | -2.1967 Cr | 2.2534 Cr | -6.6943 Cr | -0.4578 Cr | 0.1919 Cr | -2.2013 Cr | 10.0271 Cr | -3.9786 Cr | 0.0000 Cr | 4.7767 Cr |
| 2021-03-31 | 5.4770 Cr | -2.8793 Cr | -2.4507 Cr | 2.5977 Cr | 0.1470 Cr | 0.6497 Cr | -2.8793 Cr | 8.3014 Cr | -0.0191 Cr | 0.0000 Cr | -1.4646 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 96.43 Cr | 97.77 Cr | -1.34 Cr | -0.0139 | -2.34 Cr | 0.57 Cr | 0.20 | -1.51 Cr | 0.0059 |
| 2025-09-30 | 84.16 Cr | 81.36 Cr | 2.80 Cr | 0.0333 | 1.95 Cr | 1.02 Cr | 0.36 | 3.44 Cr | 0.0122 |
| 2025-06-30 | 102.21 Cr | 97.84 Cr | 4.37 Cr | 0.0428 | 1.22 Cr | 1.37 Cr | 0.48 | 3.25 Cr | 0.0134 |
| 2025-03-31 | 108.10 Cr | 108.02 Cr | 0.08 Cr | 0.0007 | -3.43 Cr | 0.47 Cr | 0.17 | 2.69 Cr | 0.0043 |
| 2024-12-31 | 133.79 Cr | 130.39 Cr | 3.40 Cr | 0.0254 | 1.62 Cr | 0.72 Cr | 0.26 | 2.88 Cr | 0.0054 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 7.19 Cr | 1.00 Cr | 8.19 Cr | 122.34 Cr | 39.12 Cr | 256.36 Cr | 25.09 Cr | 294.00 Cr | 145.15 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 3.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -138.48 Cr |
| 2025-03-31 | 1.47 Cr | 0.00 Cr | 1.47 Cr | 159.55 Cr | 45.48 Cr | 213.28 Cr | 16.22 Cr | 238.27 Cr | 99.79 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -135.59 Cr |
| 2024-09-30 | 1.49 Cr | 0.00 Cr | 1.49 Cr | 23.52 Cr | 29.84 Cr | 251.35 Cr | 12.99 Cr | 274.53 Cr | 138.94 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 0.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 0.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 1.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Chief Accountant
A. S. Kathawala
Gender: male
Year Born: 1976
Company Secretary & Compliance Officer
Kailash Chand Jethlia
Gender: male
Year Born:
Chairman & MD
Mihir Rajesh Ghatalia
Gender: male
Year Born: 1983
Executive Director
Nimit Rajesh Ghatalia
Gender: male
Year Born: 1996
Chief Financial Officer
Mira Mihir Ghatalia
Gender: female
Year Born:
FAQs about Aarey Drugs & Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mihir Rajesh Ghatalia.
What is the current market price of the stock?
The current price is ₹69.67.
What is the 52-week price range?
The range is ₹32.85-100.
What is the market capitalization of the company?
The market capitalization is ₹197.54 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 57.72.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aarey Drugs & Pharmaceuticals Limited (ISIN: INE198H01019) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹197.54 crores and an average daily volume of 280,240 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.